Drug Profile
VAD 044
Alternative Names: ALM-301; VAD-044Latest Information Update: 06 May 2024
Price :
$50
*
At a glance
- Originator Almac Discovery
- Developer Vaderis Therapeutics
- Class Antineoplastics; Small molecules; Vascular disorder therapies
- Mechanism of Action Proto oncogene protein c-akt inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Hereditary haemorrhagic telangiectasia; Vascular disorders
- Preclinical Breast cancer; Prostate cancer
Most Recent Events
- 06 May 2024 Preclinical trials in Breast cancer in Switzerland (PO) prior to May 2024 (Vaderis Therapeutics Pipeline, May 2024)
- 06 May 2024 Preclinical trials in Prostate cancer in Switzerland (PO) prior to May 2024 (Vaderis Therapeutics Pipeline, May 2024)
- 06 May 2024 Vaderis Therapeutics plans a phase III trial for Vascular disorders (Vaderis Therapeutics Pipeline, May 2024)